Trials / Withdrawn
WithdrawnNCT03245658
The Effect of Cannabis in Pancreatic Cancer
The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jens Rikardt Andersen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
Detailed description
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | THC and CBD Mixture | Individually titrated doses on daily basis |
Timeline
- Start date
- 2017-10-06
- Primary completion
- 2018-05-06
- Completion
- 2018-10-06
- First posted
- 2017-08-10
- Last updated
- 2023-12-18
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03245658. Inclusion in this directory is not an endorsement.